are important determinants identified in these isolates. The most common STs identified among these Canadian isolates have also been reported worldwide.
N eisseria gonorrhoeae, the causative agent of gonorrhea remains a global public health issue, and the World Health Organization (WHO) recently reported that approximately 88 million people yearly are affected by gonococcal infections worldwide. 1 In Canada, gonorrhea is the second most commonly reported bacterial sexually transmitted infection with over 11,000 cases reported in 2009. 2 The Canadian reported rate of gonorrhea is on the rise and has increased by 122% from 4.9 per 100,000 in 1997 to 33.1 per 100,000 in 2009. 2 N. gonorrhoeae has evolved over the years and developed resistance to many of the antibiotics used to treat it including the penicillins (PENs), tetracyclines (TETs), macrolides, and quinolones. 3 Reduced susceptibility to thirdgeneration cephalosporins has begun to develop in Asia with possible importation to Australia and Europe. 3 The earliest case reports of treatment failures with the use of thirdgeneration cephalosporins were from Japan, as early as 2000. 4 More recently, a cefixime (CFM) treatment failure for urogenital gonorrhea has been described from Norway 5 and England, 6 as well as the first reports of ceftriaxone (CRO) treatment failure of pharyngeal gonorrhea in Australia, 7 Sweden, 8 and Japan. 9 Several molecular mechanisms for decreased in vitro susceptibility and resistance to cephalosporins have been described. Two classes of penA gene alterations are possible: the first is the acquisition of a penA mosaic allele that encodes an altered PEN-binding protein 2 (PBP2); the second is an alteration of amino acids (A501, G542, P551) of PBP2 in nonmosaic penA alleles. 3, 10, 11 Mutations in the promoter and/or coding sequence of the repressor gene mtrR, which cause overexpression of the MtrCDE efflux pump system, have also been associated with a decrease in cephalosporin susceptibility. 3, 12 Finally, porB1b gene mutations (the penB resistance determinant) that alter amino acid G120 and A121 in the outer membrane PorB1b porin result in decreased permeability and, thus, further decreased susceptibility to cephalosporins. 3, 12 In this report, we present the phenotypic and genetic characteristics of N. gonorrhoeae with decreased susceptibilities to third-generation cephalosporins isolated between 2001 and 2010, results from a Canadian laboratory based antimicrobial susceptibility program coordinated by the National Microbiology Laboratory (NML), Public Health Agency of Canada.
MATERIALS AND METHODS

N. gonorrhoeae Isolates
Between January 2001 and July 2010, a total of 10,301 N. gonorrhoeae isolates were submitted from sexually transmitted infection clinics and provincial public health laboratories to the NML for antimicrobial susceptibility testing as part of the National Neisseria gonorrhoeae Surveillance Program. Isolates are submitted to the NML only when the provincial laboratories identify resistance to at least 1 antibiotic or if the provincial laboratories do not conduct any antimicrobial susceptibility testing. The results presented in this report represent N. gonorrhoeae isolates received by NML from 3 provincial public health laboratories in Canada. In addition to the isolates, information on age and sex of the patient, province of residence, date of isolation, and anatomical site of infection were also submitted to NML. Isolates in the study included those obtained from both males and females of all ages. Sexual orientation of patient was not available.
A total of 155 random isolates obtained from urethral, rectal, cervical, and pharyngeal sites displaying increased minimum inhibitory concentrations (MICs) to CFM (MIC ϭ 0.25 g/mL and 0.5 g/mL) and CRO (MIC ϭ 0.125 g/mL and 0.25 g/mL) were selected for further characterization. N. gonorrhoeae ATCC 49226, ATCC BAA-1837 (F62) and the WHO isolates WHO B, WHO C, and WHO D reference cultures were used as controls because reference cultures that exhibit decreased susceptibility to CFM and CRO were not available.
Isolate Characterization and Antimicrobial Susceptibility Testing
Antimicrobial susceptibilities of N. gonorrhoeae to azithromycin (AZM; compliments of Pfizer, Pointe-Claire/Dorval, Québec, Canada), CFM (compliments of Wyeth-Ayerst Laboratories, Mason, MI), ciprofloxacin (CIP; compliments of Bayer, Etobicoke, Ontario, Canada), spectinomycin (SPT; compliments of Pharmacia & Upjohn, Kalamazoo, MI), CRO, erythromycin (ERY), PEN, and TET (Sigma-Aldrich Canada Ltd., Oakville, Ontario, Canada) were determined using the agar dilution method with a GC medium base containing 1% Kellogg's-defined supplement and 2-fold dilutions of antibiotic. MIC (the minimum concentration of antibiotic that will inhibit the growth of the organism) interpretations were based on the criteria of the Clinical Laboratory Standards Institute: PEN resistance (R) MIC Ն2.0 g/mL; TET resistance MIC Ն2.0 g/mL; CIP resistance MIC Ն1.0 g/mL; SPT resistance MIC Ն128.0 g/mL; CRO susceptibility Յ0.25 g/mL; CFM susceptibility Յ0.25 g/mL. 13 The breakpoints for ERY and AZM resistance were both MIC Ն2.0 g/mL. ␤-lactamase production was analyzed using nitrocefin. Auxotyping and plasmid profiles were determined as previously described. 14, 15 Isolates were subcultured on GC medium base (Difco Laboratories, Detroit, MI) containing 0.2% BioX and incubated for 24 hours at 35°C in a 5% CO 2 atmosphere with or without antibiotics and maintained in brain heart infusion broth containing 20% glycerol and stored at Ϫ80°C.
N. gonorrhoeae Multiantigen Sequence Typing
The molecular genotyping of the N. gonorrhoeae isolates using the N. gonorrhoeae multiantigen sequence typing (NG-MAST) method incorporated the amplification of the porin gene (por) and the transferrin-binding protein gene (tbpB) as previously described. 16 The resulting polymerase chain reaction products were purified (QIA Quick PCR Purification Kit, Qiagen, Mississauga, Ontario or Agencourt AMPure, Beckman Coulter, Beverly, MA), and the DNA sequences of both strands obtained by the DNA Analyzer 3730xl (Applied Biosystems, Foster City, CA) were edited, assembled, and compared using software from DNAStar, Inc. (Madison, WI). The resulting sequences were submitted to the NG-MAST Web site (http://www.ng-mast.net/) to determine the sequence types (STs).
Nucleotide Sequencing of Resistance Genes penA, mtrR, ponA, and porB1b (penB Alteration)
The penA, mtrR, ponA, and porB1b (penB alteration) nucleotide sequences of the isolates were amplified as previously reported using the primers listed in Table 1 . [17] [18] [19] [20] [21] The resulting sequences were aligned with the respective gene sequences of N. gonorrhoeae wild-type strain F62 using MegAlign to identify patterns and mutations. The penA amino acid sequence patterns were classified consistent with types found by Ito et al, 17 Whiley et al, 10 and Allen et al. 22 
Genetic Analysis
Concatenated sequences of the por and tbpB alleles were created for all STs identified in this study. The evolutionary history was inferred using the Neighbor-Joining method to create a phylogenetic tree. 23 The evolutionary distances were computed using the p-distance method and are in the units of the number of base differences per site. 24 Evolutionary analyses were conducted in MAEGA5.05. 25 
Statistical Analysis
A 2 ϫ 2 2 test was used to compare 2 proportions to detect significant differences between groups of isolates (P values were calculated with a 95% confidence interval). Statistical analysis was carried out using EpiCalc 2000 version 1.02.
RESULTS
Isolate Information
A total of 155 N. gonorrhoeae isolates with increased MICs to CRO (MIC ϭ 0.125 g/mL and 0.25 g/mL) and CFM (MIC ϭ 0.25 g/mL and 0.5 g/mL) were identified from the following provinces: Ontario (53.5%, N ϭ 83); British Columbia (34.2%, N ϭ 53); Québec (12.3%, N ϭ 19 16 -58 years) . Sources of the isolates included urethral (n ϭ 26), rectal (n ϭ 18), pharyngeal (n ϭ 5), cervical (n ϭ 5), and the source for the remaining 101 isolates was unknown.
Antimicrobial Susceptibilities
The MICs of CFM and CRO as well as the antimicrobial resistance profile of all of the isolates are described in Table 2 . The majority of isolates, 95.3% (143/155) were found to be chromosomally resistant to PEN, TET, and ERY (CMRNG) or probable CMRNG (one of the MIC values of either PEN, TET or ERY ϭ 1 g/mL, the other two Ն2.0 g/mL). Based on the CLSI guidelines, 3 isolates (1.9%, 3/155) were identified as nonsusceptible (NS) to CFM (CFM-NS) (MIC ϭ 0.5 g/mL). Each of these 3 isolates was also resistant to other antimicrobials: one CFM-NS/CIP-R; one CFM-NS/CIP-R/ERY-R; one CFM-NS/PEN-R/TET-R/CIP-R. A total of 3.8% of isolates (6/155) were found to be resistant to one antimicrobial, CIP. Two isolates were identified as CIP-R/TET-R, and the remaining isolate was found to have high-level plasmid-mediated TET resistance (TRNG)/CIP-R/ERY-R, harboring the 25.2-Mda plasmid along with the 2.6-Mda cryptic plasmid. All but one of the isolates were found to harbor the 2.6-Mda cryptic plasmid. Auxotyping revealed that 61.9% (96/155) were proline-requiring, 37.4% (58/155) were nonrequiring isolates, and 1 (0.6%) was identified as a hypoxanthine-requiring isolate. All 155 isolates were susceptible to SPT, AZM, and CRO.
Based on all N. gonorrhoeae isolates submitted to NML, a right shift in the modal MICs of both CRO and CFM has been observed between 2001 and 2010, from 0.016 to 0.125 g/mL for CFM and from 0.016 to 0.063 g/mL for CRO during this time period. In 2001, 27.8% and 32.0% of all isolates tested (N ϭ 1058) had MICs equal to 0.016 g/mL for CRO and CFM, respectively. By 2010, 29 .8% of all isolates tested (N ϭ 503) had a CFM MICs equal to 0.125 g/mL and 35.8% had a CRO MIC equal to 0.063 g/mL (Fig. 1) .
Mutations in the penA Gene
Sequencing of the penA gene revealed that 60% (93/155) of the isolates contained the penA mosaic allele. The sequence pattern types observed in these isolates included pattern XXXII (84.9%, 79/93), X (12.9%, 12/93), and XXXVIII (2.2%, 2/93). The remaining 40% (62/155) non-penA mosaic allele isolates had sequence pattern type XII (91.9%, 57/62), V (4.8%, 3/62), XIII (1.6%, 1/62), and a pattern type previously not identified (1.6%, 1/62). This new pattern designated XXXIX was deposited into GenBank under the accession number JF893455. It displayed the D345A insertion typical of non-penA mosaic types; however, it lacked any of the other amino acid mutations associated with these types. It also has combinations of the mutations identified in mosaic patterns X and XXXII as shown in Figure Geographically, penA pattern XII was identified at significantly higher rates in Ontario (51.8%) and Québec (63.2%) as compared with British Columbia (3.8%, P Ͻ 0.001). However, British Columbia had significantly more penA pattern XXXII isolates (86.8%) than Ontario (32.5%) or Québec (31.6%, P Ͻ 0.001).
Of the 62 isolates with nonmosaic penA alleles, 93.5% (58/62) and 4.8% (3/62) had the amino acid substitution P551S and G542S, respectively. One isolate (1.6%) was identified as having the A501V mutation of the penA gene. This isolate, which also had the P551S mutation, was found to be a penA type XIII. Other mutations identified in this isolate include the mtrR deletion of A, the ponA L421P and the porB1b (penB alterations) G120K and A121G.
Mutations in the mtrR Gene
A single nucleotide (A) deletion in the 13-bp inverted repeat located between the Ϫ10 and Ϫ35 sequence of the mtrR promoter region that causes overexpression of the MtrCDE efflux pump was identified in 95.5% (148/155) of the isolates. Four of these isolates (2.6%) also displayed a G45D alteration in addition to the promoter region A deletion. Three isolates (1.9%) did not have the well-described A deletion in the promoter region but 2 of these displayed a G45D alteration, and 1 had an A39T alteration. A total of 2.6% (4/155) isolates did not have the A deletion in the promoter region or any other alteration in mtrR.
Mutations in the porB1b and ponA Genes
All 155 isolates displayed alterations in porB1b (penB alteration), including G120K, A121N (49.7%, 77/155); G120K, A121D (45.2%, 70/155); G120K, A121G (2.6%, 4/155); and G120R, A121D (0.6%, 1/155). Three isolates (1.9%) did not have alterations in amino acid 120 but did have the A121S alteration. The ponA alteration L421P was detected in all of the isolates. Alterations in penA, mtrR, ponA, porB1b (penB alteration) for all the isolates are displayed in Table 2 .
Comparison of NG-MAST Data
Thirty-seven different NG-MAST STs were identified among the isolates; ST3158, ST225, and ST1407 were the most prevalent at 25.8%, 19.4%, and 14.8%, respectively. There were no statistically significant differences in distribution of most STs over time except for an increase in proportion of ST1407 from 1.2% in 2008 to 28.0% in 2010 (P Ͻ 0.001). Geographically, significantly more ST225 were found in Ontario (27.7%, P Ͻ 0.001) and Québec (31.6%, P Ͻ 0.001) than in British Columbia (1.9%). Of the 37 STs, 16 STs had not been identified in the NG-MAST database and were newly identified in this study. Twenty-three (14.8%) STs were represented by only 1 isolate. Of the 37 different STs, 11 STs all contained the tbpB-110 allele which represented 51.6% (80/155) isolates. Figure 3 demonstrates the evolutionary relationships between the STs found in this study. It reveals how ST225 is very closely related to 6 other STs including ST3132, ST4428, ST3599, ST4433, ST4434, and ST3123 (Subtree A). Subtree A represents 26.4% (41/155) of the isolates in this study, and all isolates in Subtree A differ by 1 nucleotide. All of the isolates in Subtree A are the nonmosaic penA pattern type XII, contain the mtrR A deletion, the ponA L421P mutation, and the porB1b (penB alteration) G120K and A121D mutations. which is a slightly modified version of type XXXII. All Subtree B isolates have the mtrR A deletion, the ponA L421P and porB1b (penB alteration) G120K and A121N mutations. An additional 9 different STs differing from Subtree B by up to 45 nucleotides can be included in this cluster for a total of 55.5% (86/155) of all isolates in this study.
DISCUSSION
The upward shift of MICs in third-generation cephalosporins in N. gonorrhoeae has been described in many countries worldwide and is particularly worrisome as these are the last remaining treatment options to cure gonorrhea. This study describes the genotypic and phenotypic characteristics of N. gonorrhoeae, found to be resistant to at least one antibiotic, isolated in Canada between 2001 and mid-2010 with reduced susceptibility to third-generation cephalosporins. Monitoring MICs over time, the detection of penA mosaic alleles as well as the identification of alterations A501, G542, P551 in PBP2 and the characterization of mtrR and porB1b (penB alterations) determinants become very important for surveillance purposes and to monitor the emergence and spread of isolates with decreased third-generation cephalosporins susceptibility. The relationship of these genetic determinants and the increase in MICs to cephalosporins has been well described. 3, 12, 26 The majority of the isolates in this study had both the penA mosaic allele and nonmosaic allele sequence pattern types that have been previously reported and 1 nonmosaic allele isolate with a novel sequence pattern type. Regarding the non-penA mosaic allele mutations, our study identified 1 isolate with the A501V mutation of the penA gene, in contrast with reports from countries such as Sweden 27 and Japan. 11 However, the majority of our non-penA mosaic isolates did have either Figure 3 . Phylogenetic reconstruction of concatenated sequences of por and tbpB alleles for all sequence types (STs) in this study. Two major subtrees were found surrounding the most prevalent STs (ST225, ST1407, and ST3158). The 2 subtrees are genetically separated by approximately 74 nucleotides. The evolutionary history was inferred using the neighbor-joining method. 24 The optimal tree with the sum of branch length ϭ 0.67455331 is shown. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the p-distance method 23 and are in the units of the number of base differences per site. The analysis involved 37 nucleotide sequences. Codon positions included were 1st ϩ 2nd ϩ 3rd ϩ Noncoding. All positions containing gaps and missing data were eliminated. There were a total of 810 positions in the final dataset. Evolutionary analyses were conducted in MEGA5.05. 25 Characterization of N. gonorrhoeae Isolates Sexually Transmitted Diseases • Volume 39, Number 4, April 2012 P551S or G542S mutations, which were recently linked to decreased susceptibility to CRO. 26 Monitoring these penA alterations in combination with the mtrR deletion and porB1b mutations is important in understanding the progression of N. gonorrhoeae as the MICs to the third-generation cephalosporins continue to increase. Alterations L421P in ponA (encoding PBP1) have also been previously suggested to contribute to the decreased susceptibility to third-generation cephalosporins. All the isolates tested in this study did in fact have the L421P ponA alteration. However, recent studies have shown that, in contrast with the PENs, ponA alterations do not significantly affect susceptibility to thirdgeneration cephalosporins in N. gonorrhoeae. 12 An ST cluster analysis revealed that the majority of all the isolates studied belonged to 5 different STs and some of these STs were highly related, indicating a clonal relationship between many of these Canadian isolates. This clonal distribution of isolates is similar to a recent report from England. 6 In contrast, other studies from Sweden 27 and Australia 10 have reported a higher degree of diversity amongst their reduced susceptibility gonococci. Part of the collection of Canadian isolates did in fact have a high degree of diversity, which can be explained by the high polymorphism of the 2 alleles involved in the NG-MAST method. A large number of isolates belonged to a single unique ST, which may be due to the local emergence of new STs or the recent introduction of gonorrhea from other countries. At least two of the STs identified in these Canadian isolates have been reported in other countries including England, the United States, and Australia. 6, 28, 29 ST1407 is very closely related to ST3158, reported in Ontario, Canada by Allen et al 22 and also identified in Sweden. 27 As reports of decreased susceptibility to third-generation cephalosporins in N. gonorrhoeae continue, gonococcal treatment guidelines are being reviewed. In a recent report, Chisholm et al 30 describe that gonococci with CRO and CFM MICs of 0.125 to 0.25 g/mL are likely to be on the edge of responsiveness to current treatments and suggest strategies to control antimicrobial resistance in gonorrhea, including higher cephalosporin doses, multidose cephalosporin regimens, and drug cycling. Furthermore, pharmacodynamic analysis predicts that failures with the standard 400-mg CFM orally and 250-mg CRO intramuscularly treatments become possible around these MICs. 30 A major challenge faced by the laboratories that perform surveillance of antimicrobial resistance of N. gonorrhoeae is the shift from the use of cultures (currently required for antimicrobial susceptibility testing) to the Nucleic Acid Amplification Test for the diagnosis of gonorrhea, explaining the decrease in the number of isolates available for susceptibility testing and interfering with clinical treatment. The current passive Canadian surveillance system for N. gonorrhoeae is limited by the collection of only resistant isolates, which may introduce a bias and cause a lack of representativeness. In response, the current Canadian surveillance system for N. gonorrhoeae is being strengthened through a sentinel cliniclaboratory surveillance mechanism capable of integrating epidemiologic, laboratory, and treatment failure information for both drug-sensitive and drug-resistant N. gonorrhoeae. Such a mechanism is imperative for both patient management and surveillance purposes as multidrug resistant N. gonorrhoeae with decreasing susceptibilities to third-generation cephalosporins are emerging.
